HLB Therapeutics' Neurotrophic Keratitis Treatment Fails to Achieve Statistical Significance for Primary Endpoint
HLB Therapeutics said its U.S. subsidiary Regentree failed to achieve statistical significance for the primary endpoint in the topline results of the U.S. Phase 3 clinical trial (SEER-2) of RGN-259, a treatment for neurotrophic keratitis (NK).
According to data HLB Therapeutics received from the contract research organization (CRO) on November 16, there was no statistically significant difference in the healing rate four weeks after treatment, the primary endpoint, between the RGN-259 treatment group and the placebo group.
The company plans to officially receive the full clinical trial data from the CRO within the next few weeks. It will then comprehensively review detailed results for the primary endpoint, as well as secondary endpoints and treatment responses by subgroup, and conduct an in-depth analysis of the clinical results.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
"Although the topline results did not show statistical significance for the primary endpoint, we plan to thoroughly analyze the full clinical data and comprehensively assess the detailed results related to treatment efficacy," said HLB Therapeutics CEO Ahn Kihong. "Based on the analysis, we will carefully review our future development direction and plans, and promptly and responsibly take any necessary follow-up measures."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.